Dongbao Pharmaceutical
Financials
Estimates*
| CNY | 2019 | 2020 | 2021 | 2022 | 2023 | 2025 |
|---|---|---|---|---|---|---|
| Revenues | 2.8b | 2.9b | 3.3b | 2.8b | 3.1b | 27.7b |
| % growth | - | 4 % | 13 % | (15 %) | 11 % | - |
| EBITDA | 1.1b | 1.3b | 1.7b | 2.0b | 1.6b | - |
| % EBITDA margin | 41 % | 44 % | 52 % | 71 % | 52 % | - |
| Profit | 811m | 930m | 1.3b | 1.6b | 1.2b | - |
| % profit margin | 29 % | 32 % | 40 % | 57 % | 38 % | - |
| R&D budget | 78.0m | 107m | 167m | 147m | 105m | - |
| R&D % of revenue | 3 % | 4 % | 5 % | 5 % | 3 % | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
$283m | Growth Equity VC | ||
| Total Funding | €257m | ||
Related Content
Recent News about Dongbao Pharmaceutical
EditTonghua Dongbao Pharmaceutical Co., Ltd. is a leading biopharmaceutical company specializing in the development and commercialization of high-end recombinant protein products and treatments for endocrine and metabolic disorders. Operating primarily in the Chinese market, the company serves both consumer and professional healthcare sectors. Tonghua Dongbao's business model revolves around continuous innovation and upgrading of its technology platforms to expand its product line and market segments. The company generates revenue through the sale of its proprietary biopharmaceutical products, including recombinant human insulin and GLP-1 receptor agonists like liraglutide and semaglutide injections. Recent developments include the approval of 1RA Liraglutide injection for marketing and the acceptance of etoricoxib tablets by the NMPA. The company also focuses on sustainable practices such as acetonitrile recycling and wastewater treatment. Tonghua Dongbao's strategic partnerships and funding rounds aim to leverage expertise and resources to accelerate growth and ensure long-term success.
Keywords: biopharmaceutical, recombinant proteins, endocrine treatments, metabolic disorders, innovation, technology platforms, Chinese market, insulin, GLP-1 agonists, sustainable practices.
